PRIA Logo™
119-hr-2471119th CongressWALLET

Right Drug Dose Now Act of 2025

Sponsored By: Representative Swalwell, Eric [D-CA-14]

Introduced

Summary

Brings pharmacogenomic testing into routine prescribing to reduce adverse drug reactions. This bill would push federal agencies and health systems to use genetic information to prevent harmful drug-gene and drug-drug-gene interactions and to improve reporting and electronic health record tools.

Show full summary
  • Patients and families: Encourages consideration of pharmacogenomic testing as part of care and asks HHS to report on progress toward national prevention targets within 180 days. This aims to lower medication harms by tailoring drugs to genetic profiles.
  • Clinicians and health leaders: Requires HHS guidance on when to test, how to consult genetics experts, and how to use test results in medication management. It also asks for regular updates to drug-gene alerting guidance at least twice a year.
  • Health IT vendors and pharmacies: Directs improvements to electronic health records and e-prescribing so alerts can recommend testing before orders are completed and accept testing results from labs.
  • Federal systems and regulators: Directs upgrades to FDA's adverse event system to accept EHR-submitted pharmacogenomic data, adds a patient-friendly electronic reporting option, and orders studies on drug labels and EHR changes within 180 days.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

Update national plan for safer medicines

If enacted, HHS would report to Congress within 180 days on progress preventing adverse drug events. The Secretary would reconvene the federal steering committee to update the national plan. The update would review new science on drug‑gene interactions, falling genetic test costs, and real‑world outcomes. It would assess when genetic testing plus clinical decision tools can prevent harm. It would also expand federal monitoring to spot genetic links in adverse events.

Easier reporting of genetic drug side effects

If enacted, HHS would update the FDA’s adverse event system to accept reports from EHRs and to mark drug‑gene links. The government would work with partners to create easy, patient‑friendly reporting options, like a mobile app. HHS would report to Congress on these updates within 1 year of enactment. HHS would also send Congress a report within 180 days on EHR upgrades needed to record the lab and exact test used for genetic drug testing.

Guidance for doctors on genetic drug tests

If passed, HHS would issue guidance to doctors and health IT teams on using pharmacogenomic tests. It would explain when testing is appropriate and when to consult genetics experts. It would tell e‑prescribing and EHR systems to flag needed tests and drug‑gene risks before a medication order is finished. It would show how to fold genetics into medication management and how to report this info to the FDA. HHS would update the drug‑gene alerting guidance at least twice a year.

Sponsors & CoSponsors

Sponsor

Swalwell, Eric [D-CA-14]

CA • D

Cosponsors

  • Rep. Crenshaw, Dan [R-TX-2]

    TX • R

    Sponsored 3/27/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation